ArticleVaccines2026
Cost-Effectiveness and Budget Impact Analysis of the Trivalent Adjuvanted Influenza Vaccine in People over 50 Years of Age for Argentina.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundInfluenza imposes a substantial burden on Argentina, particularly among adults aged 50-64 with comorbidities and those aged ≥65. The adjuvanted trivalent influenza vaccine (aTIV) has shown superior effectiveness compared with non-adjuvanted vaccines; however, its cost-effectiveness and budget impact in the 50-64 high-risk population have not been assessed nationally. This study evaluates the cost-effectiveness and budget impact of introducing aTIV for high-risk adults aged 50-64, alongside its use in adults aged ≥65, compared with standard-dose trivalent influenza vaccine (SD-TIV) from the Argentine health care system perspective.
methodsA decision-analytic static model was used to compare aTIV with SD-TIV over a single influenza season. In addition, a 5-year budget impact analysis (BIA) was conducted under scenarios of progressive uptake. Model inputs were derived from international literature, local data, and expert opinion. Deterministic and probabilistic sensitivity analyses were performed.
resultsCompared with SD-TIV, aTIV yielded a lifetime gain of 1489 quality-adjusted life-years (QALYs) at an incremental cost of USD 8.34 million, resulting in an incremental cost-effectiveness ratio (ICER) of USD 5599 per QALY gained-well below Argentina's cost-effectiveness threshold (USD 11,059/QALY). Higher vaccine acquisition costs were largely offset by reductions in outpatient visits and hospitalizations. The BIA showed a modest average annual per-member-per-month increase of USD 0.0025, remaining below the estimated budget impact threshold (USD 0.0065).
conclusionsImplementing aTIV in adults aged ≥50 with risk factors would be cost-effective and affordable in Argentina. These findings support the consolidation and potential expansion of current vaccination strategies to reduce influenza burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.